Keywords: Johnson & Johnson, 2009 results,
Johnson & Johnson’s 4th-qtr/full year 2009 sales and profit exceed expectations, but forecast disappoints
Article | 27 January 2010
US health care giant Johnson & Johnson has posted better-than-expected fourth-quarter and full year 2009 sales and earnings, helped by sharply ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
